Smoking and depressive symptoms in Chinese patients with first-episode drug-naïve schizophrenia

作者：Shuochi Wei, Dongmei Wang, Huixia Zhou, Li Wang, Xiaoer Lang, Xiangyang Zhang · 年份：2023 · DOI：10.22541/au.167844980.08963981/v1 · 研究领域：Neurotransmitter Receptor Influence on Behavior、Tryptophan and brain disorders

Objective: The prevalence of smoking and depressive symptoms in patients with schizophrenia (SCZ) is high. However, few studies have examined the relationship between smoking and depressive symptoms in patients with first-episode SCZ. In this study, we investigated the prevalence and risk factors of smoking and its relationship with depressive symptoms in Chinese male patients with first-episode drug-naïve (FEDN) SCZ. Methods: We recruited 164 male patients with FEDN SCZ, including 58 current smokers and 106 nonsmokers. Patients completed a detailed questionnaire about smoking status, age of onset, body mass index (BMI), and other socio-demographic data. We used the Positive and Negative Syndrome Scale (PANSS), the 24-item Hamilton Rating Scale for Depression (HDRS), and the Hamilton Rating Scale for Anxiety (HARS) to assess the clinical symptoms of patients. Results: The current smoking rate of FEDN SCZ patients was 35.36%. Compared to nonsmokers, current smokers were older, had a later age of onset, fewer years of education, and a larger BMI. Smoking patients had higher HDRS score than nonsmoking patients (39.83±12.32 vs. 34.97±11.88, F1,162=6.10, p<0.05). Logistic regression analysis showed that the HDRS score was significantly associated with patients’ smoking status (Wald χ2 =4.01, df=1, p<0.05, OR=1.05; 95%CI: 1.001~1.104). Conclusions: Our results suggest that the prevalence of smoking in patients with FEDN SCZ is similar to that of healthy individuals. Some demo...